Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2003
03/06/2003WO2003018591A1 Novel pseudolaric acid-b derivatives, their preparation and pharmaceutical compositions
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018576A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
03/06/2003WO2003018574A1 Rapamycin dialdehydes
03/06/2003WO2003018573A1 Rapamycin 29-enols
03/06/2003WO2003018566A1 New piperidinyl derivates as modulators of chemokine receptor activity
03/06/2003WO2003018563A1 Anti-inflammatory and protein kinase inhibitor composition and method of use
03/06/2003WO2003018557A1 Hydrazinopeptoids and their uses for treating cancers
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018554A1 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
03/06/2003WO2003018545A1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3?
03/06/2003WO2003018536A1 Chemotherapeutic agents
03/06/2003WO2003018135A1 Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
03/06/2003WO2003018134A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003WO2003018065A1 Anti-cancer agents comprising disintegrin genes and the treating methods
03/06/2003WO2003018062A1 Improved therapeutic protocols
03/06/2003WO2003018048A1 Use of hla class 1 soluble molecules to inhibit angiogenesis
03/06/2003WO2003018044A1 New drug
03/06/2003WO2003018036A1 Composition for detection and/or treatment of lesions & tumours
03/06/2003WO2003018022A1 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
03/06/2003WO2003018021A1 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003018018A2 Vinorelbine compositions and methods of use
03/06/2003WO2003018014A2 Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
03/06/2003WO2003018007A1 Antitumor agents and process for producing the same
03/06/2003WO2003018002A2 Cyclopropyl and cyclobutyl epothilone analogs
03/06/2003WO2003017998A1 Platinum complexes and their use in cancer treatment
03/06/2003WO2003017996A1 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
03/06/2003WO2003017993A1 Photoreactive compounds and compositions
03/06/2003WO2003017983A1 A new extended release oral dosage form
03/06/2003WO2003017982A1 A new extended release oral dosage form
03/06/2003WO2003017946A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003WO2003017940A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
03/06/2003WO2003017939A2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
03/06/2003WO2003017935A2 Human antibodies specific for interleukin 15 (il-15)
03/06/2003WO2003017846A1 Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy
03/06/2003WO2003017757A1 Rat with the onset of hereditary renal cancer and causative gene thereof
03/06/2003WO2002096367A3 Targeted multivalent macromolecules
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085945A3 Vhh single heavy chain antibody and a method for its preparation in a mammal
03/06/2003WO2002083171A3 Cancer treatment by using fap-alpha specific antibodies
03/06/2003WO2002081709A3 Modified hpv e6 and e7 genes and proteins useful for vaccination
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002074243A9 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002066415A8 Non-steroidal modulators of estrogen receptors
03/06/2003WO2002064731A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
03/06/2003WO2002060972A3 Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
03/06/2003WO2002060929A3 Polymer conjugates of neublastin and methods of using same
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002059264A3 Specific human antibodies for selective cancer therapy
03/06/2003WO2002055507A8 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
03/06/2003WO2002055106A3 Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
03/06/2003WO2002051994A8 Polypeptides
03/06/2003WO2002043661B1 Recombinant anti-cd30 antibodies and uses thereof
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002031151A3 Lipocalins
03/06/2003WO2002030982A3 Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
03/06/2003WO2002028481A3 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
03/06/2003WO2002028409A3 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
03/06/2003WO2002026947A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/06/2003WO2002020516A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
03/06/2003WO2002014500A3 Human genes and gene expression products
03/06/2003WO2002012281A9 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
03/06/2003WO2002000650A9 Novel compounds possessing antibacterial, antifungal or antitumor activity
03/06/2003WO2001098343A9 Conserved diaphanous-related formin autoregulatory domain (dad)
03/06/2003WO2001092525A8 Compositions and methods for the therapy and diagnosis of lung cancer
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001090313A9 METHODS FOR ASSAYING GENE IMPRINTING AND METHYLATED CpG ISLANDS
03/06/2003WO2001077146A3 Compounds and methods for modulating endothelial cell adhesion
03/06/2003WO2001072781A9 Human genes and expression products
03/06/2003WO2001068076A3 D-enantiomer of dfmo and methods of use thereof for treating cancer
03/06/2003WO2001066741A9 Kcnb: a novel potassium channel protein
03/06/2003WO2001055393A9 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
03/06/2003US20030046714 Anti-neovasculature preparations for cancer
03/06/2003US20030045755 Polyamine analogues as cytotoxic agents
03/06/2003US20030045742 Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045695 Ribozyme for detecting gene sequence
03/06/2003US20030045682 Antibodies immunospecific for STEAP1
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045556 Aryl-N-cyanoguanidines and methods related thereto
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045552 Isoindole-imide compounds, compositions, and uses thereof
03/06/2003US20030045546 Anticancer agents
03/06/2003US20030045545 Immunomodulators, induce cytokine biosynthesis, and antineoplastic agents
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045537 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same
03/06/2003US20030045535 Antiproliferative and antitumor agents
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045518 Certain bis(thio-hydrazide amide) compounds significantly enhance the anticancer activity of taxol.
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045496 Treating tumor cells with a selenium prodrug lyase and a selenium-containing prodrug such as selenocysteine, selenohomocysteine, selenomethionine or selenoethionine.
03/06/2003US20030045494 Synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor
03/06/2003US20030045493 Oligonucleotide compositions and their use to induce differentiation of cells
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045483 Novel substance having physiological activity, process for producing the same, and use
03/06/2003US20030045466 Calcium binding protein
03/06/2003US20030045456 Complex comprising OCIF and polysaccharide
03/06/2003US20030044975 Cytokine-binding domain for use in the treatment of asthma and thrombocytopenia
1 ... 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 ... 2211